These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35415210)

  • 1. Characterization of cerebrospinal fluid biomarkers associated with neurodegenerative diseases in healthy cynomolgus and rhesus macaque monkeys.
    Robertson EL; Boehnke SE; Lyra E Silva NM; Armitage-Brown B; Winterborn A; Cook DJ; De Felice FG; Munoz DP
    Alzheimers Dement (N Y); 2022; 8(1):e12289. PubMed ID: 35415210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of lumbar puncture on the neurodegeneration biomarker neurofilament light in macaque monkeys.
    Boehnke SE; Robertson EL; Armitage-Brown B; Wither RG; Lyra E Silva NM; Winterborn A; Levy R; Cook DJ; De Felice FG; Munoz DP
    Alzheimers Dement (Amst); 2020; 12(1):e12069. PubMed ID: 32695873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
    Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
    J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study.
    Abu-Rumeileh S; Giannini G; Polischi B; Albini-Riccioli L; Milletti D; Oppi F; Stanzani-Maserati M; Capellari S; Mantovani P; Palandri G; Cortelli P; Cevoli S; Parchi P
    J Alzheimers Dis; 2019; 68(2):723-733. PubMed ID: 30883350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of Plasma Amyloid β, Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer's Disease in South China.
    Jiao B; Liu H; Guo L; Liao X; Zhou Y; Weng L; Xiao X; Zhou L; Wang X; Jiang Y; Yang Q; Zhu Y; Zhou L; Zhang W; Wang J; Yan X; Tang B; Shen L
    Front Aging Neurosci; 2021; 13():749649. PubMed ID: 34776933
    [No Abstract]   [Full Text] [Related]  

  • 6. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
    Seino Y; Nakamura T; Kawarabayashi T; Hirohata M; Narita S; Wakasaya Y; Kaito K; Ueda T; Harigaya Y; Shoji M
    J Alzheimers Dis; 2019; 68(1):395-404. PubMed ID: 30814356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.
    Banerjee G; Ambler G; Keshavan A; Paterson RW; Foiani MS; Toombs J; Heslegrave A; Dickson JC; Fraioli F; Groves AM; Lunn MP; Fox NC; Zetterberg H; Schott JM; Werring DJ
    J Alzheimers Dis; 2020; 74(4):1189-1201. PubMed ID: 32176643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
    Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
    Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease related biomarkers in bipolar disorder - A longitudinal one-year case-control study.
    Knorr U; Simonsen AH; Jensen CS; Zetterberg H; Blennow K; Akhøj M; Forman J; Hasselbalch SG; Kessing LV
    J Affect Disord; 2022 Jan; 297():623-633. PubMed ID: 34728295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal Fluid Biomarkers to Differentiate Idiopathic Normal Pressure Hydrocephalus from Subcortical Ischemic Vascular Disease.
    Manniche C; Simonsen AH; Hasselbalch SG; Andreasson U; Zetterberg H; Blennow K; Høgh P; Juhler M; Hejl AM
    J Alzheimers Dis; 2020; 75(3):937-947. PubMed ID: 32390628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal Fluid Alzheimer's Biomarkers and Neurofilament Light Profile of Idiopathic Normal Pressure Hydrocephalus in China: A PUMCH Cohort Study.
    Mao C; Sha L; Liu C; Chu S; Li J; Huang X; Lei D; Wang J; Dong L; Xu Q; Peng B; Cui LY; Gao J
    Neurodegener Dis; 2020; 20(5-6):165-172. PubMed ID: 34077945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings.
    Blennow K; Zetterberg H
    Prog Mol Biol Transl Sci; 2019; 168():3-23. PubMed ID: 31699324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
    de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
    Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
    Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
    J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation.
    Racine AM; Koscik RL; Nicholas CR; Clark LR; Okonkwo OC; Oh JM; Hillmer AT; Murali D; Barnhart TE; Betthauser TJ; Gallagher CL; Rowley HA; Dowling NM; Asthana S; Bendlin BB; Blennow K; Zetterberg H; Carlsson CM; Christian BT; Johnson SC
    Alzheimers Dement (Amst); 2016; 2():27-38. PubMed ID: 26955655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease.
    Shi Y; Lu X; Zhang L; Shu H; Gu L; Wang Z; Gao L; Zhu J; Zhang H; Zhou D; Zhang Z
    ACS Chem Neurosci; 2019 Aug; 10(8):3479-3485. PubMed ID: 31145586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up.
    Bruzova M; Rusina R; Stejskalova Z; Matej R
    Sci Rep; 2021 May; 11(1):10837. PubMed ID: 34035398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.
    Kern S; Syrjanen JA; Blennow K; Zetterberg H; Skoog I; Waern M; Hagen CE; van Harten AC; Knopman DS; Jack CR; Petersen RC; Mielke MM
    JAMA Neurol; 2019 Feb; 76(2):187-193. PubMed ID: 30419087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.